CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

Published:2017-12 Issue:6 Volume:72 Page:962-971
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Escudier Bernard,Sharma Padmanee,McDermott David F.,George Saby,Hammers Hans J.,Srinivas Sandhya,Tykodi Scott S.,Sosman Jeffrey A.,Procopio Giuseppe,Plimack Elizabeth R.,Castellano Daniel,Gurney Howard,Donskov Frede,Peltola Katriina,Wagstaff John,Gauler Thomas C.,Ueda Takeshi,Zhao Huanyu,Waxman Ian M.,Motzer Robert J.

Publisher

Elsevier BV

Subject

Urology

Reference24 articles.

1. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study;Heng;J Clin Oncol,2009

2. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2004

3. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy;McKay;Eur Urol,2014

4. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study;Calvo;Eur J Cancer,2012

5. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial;Escudier;Br J Cancer,2014

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implications of bone metastasis on response to systemic therapy in patients with advanced renal cell carcinoma: A systematic literature review;Cancer Treatment Reviews;2024-09

2. Budget impact models for lung cancer interventions: A systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

3. Notfälle in der Medikamentösen Tumortherapie;TumorDiagnostik & Therapie;2024-09

4. Effectiveness of modern immunotherapy in combination treatment of patients with renal cancer and bone metastases;Cancer Urology;2024-08-15

5. Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments;Biochemical Pharmacology;2024-08